These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

431 related items for PubMed ID: 1903080

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis.
    Martin U, Fischer S, Sponer G.
    J Am Coll Cardiol; 1993 Sep; 22(3):914-20. PubMed ID: 8354832
    [Abstract] [Full Text] [Related]

  • 4. Accelerated intravenous dosing of recombinant tissue-type plasminogen activator causes rapid but unstable reperfusion in a canine model of acute myocardial infarction.
    Gurbel PA, Anderson RD, MacCord CS, Scott H, Serebruany V, Herzog WR.
    Coron Artery Dis; 1994 Nov; 5(11):929-36. PubMed ID: 7719525
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition.
    Lynch JJ, Sitko GR, Mellott MJ, Nutt EM, Lehman ED, Friedman PA, Dunwiddie CT, Vlasuk GP.
    Cardiovasc Res; 1994 Jan; 28(1):78-85. PubMed ID: 8111795
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Thrombolytic activity of a novel modified tissue-type plasminogen activator, YM866, in a canine model of coronary artery thrombosis.
    Kawasaki T, Katoh M, Kaku S, Gushima H, Takenaka T, Yui Y, Kawai C.
    Jpn J Pharmacol; 1993 Sep; 63(1):9-16. PubMed ID: 8271535
    [Abstract] [Full Text] [Related]

  • 11. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators.
    Smalling RW, Bode C, Kalbfleisch J, Sen S, Limbourg P, Forycki F, Habib G, Feldman R, Hohnloser S, Seals A.
    Circulation; 1995 Jun 01; 91(11):2725-32. PubMed ID: 7758177
    [Abstract] [Full Text] [Related]

  • 12. Recombinant single-chain urokinase-type plasminogen activator (rscu-PA) induces thrombolysis and systemic fibrinolysis in a canine model of coronary artery thrombosis.
    Söhngen W, Mickelson JK, Simpson PJ, Lucchesi BR.
    Thromb Res; 1988 Jul 01; 51(1):63-74. PubMed ID: 3137691
    [Abstract] [Full Text] [Related]

  • 13. Double bolus administration of the novel recombinant plasminogen activator BM 06.022 improves coronary blood flow after reperfusion in a canine model of coronary thrombosis.
    Martin U, Sponer G, König R, Smolarz A, Meyer-Sabellek W, Strein K.
    Blood Coagul Fibrinolysis; 1992 Apr 01; 3(2):139-47. PubMed ID: 1606285
    [Abstract] [Full Text] [Related]

  • 14. Enhanced thrombolysis, reduced coronary reocclusion and limitation of infarct size with liposomal prostaglandin E1 in a canine thrombolysis model.
    Feld S, Li G, Amirian J, Felli P, Vaughn WK, Accad M, Tolleson TR, Swenson C, Ostro M, Smalling RW.
    J Am Coll Cardiol; 1994 Nov 01; 24(5):1382-90. PubMed ID: 7930264
    [Abstract] [Full Text] [Related]

  • 15. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
    Nicolini FA, Nichols WW, Saldeen TG, Mehta JL.
    Cardiovasc Res; 1991 Apr 01; 25(4):283-9. PubMed ID: 1909212
    [Abstract] [Full Text] [Related]

  • 16. Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.
    Rapold HJ, Wu ZM, Stassen T, Van de Werf F, Collen D.
    Blood; 1990 Oct 15; 76(8):1558-63. PubMed ID: 2119830
    [Abstract] [Full Text] [Related]

  • 17. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
    Golino P, Rosolowsky M, Yao SK, McNatt J, De Clerck F, Buja LM, Willerson JT.
    J Clin Invest; 1990 Oct 15; 86(4):1095-102. PubMed ID: 2145320
    [Abstract] [Full Text] [Related]

  • 18. Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.
    Golino P, Ashton JH, McNatt J, Glas-Greenwalt P, Yao SK, O'Brien RA, Buja LM, Willerson JT.
    Circulation; 1989 Apr 15; 79(4):911-9. PubMed ID: 2494005
    [Abstract] [Full Text] [Related]

  • 19. Heparin and the thrombin inhibitor argatroban enhance fibrinolysis by infused or bolus-injected saruplase (r-scu-PA) in rabbit femoral artery thrombosis.
    Schneider J.
    Thromb Res; 1991 Dec 15; 64(6):677-89. PubMed ID: 1798957
    [Abstract] [Full Text] [Related]

  • 20. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
    Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP.
    Circulation; 1992 Feb 15; 85(2):805-15. PubMed ID: 1735171
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.